Examinando por Autor "Arguedas, Mauricio"

Seleccione resultados tecleando las primeras letras
Mostrando 1 - 2 de 2
  • Miniatura
    Ítem
    Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19
    (Los autores, 2021-09) Sánchez, Andrés; Alape-Girón, Alberto; Moreira-Soto, Andrés; Arguedas, Mauricio; Brenes, Hebleen; Buján, Willem; Corrales-Aguilar, Eugenia; Díaz, Cecilia; Echeverri, Ann; Flores-Díaz, Marietta; Gómez, Aarón; Hernández, Andrés; Herrera, María; León, Guillermo; Macaya, Román; Molina-Mora, José Arturo; Mora, Javier; Narayanan, Aarthi; Sanabria, Alfredo; Sánchez, Laura; Segura, Álvaro; Segura, Eduardo; Solano, Daniela; Soto, Claudio; Stynoski, Jennifer L; Vargas, Mariángela; Villalta, Mauren; Drexler, Jan Felix; Gutiérrez, José María
    The emergence and dissemination of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting COVID-19 pandemic triggered a global public health crisis. Although several SARS-CoV-2 vaccines have been developed, demand far exceeds supply, access to them is inequitable, and thus, populations in low- and middle-income countries are unlikely to be protected soon (1). Furthermore, there are no specific therapies available, which is a challenge for COVID-19 patient care (2). Thus, the appearance of SARS-CoV-2 variants and reports of reinfections associated with immune escape (3, 4) highlight the urgent need for effective and broad coverage COVID-19 therapeutics
  • Miniatura
    Ítem
    High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern
    (los autores, 2022) Moreira-Soto, Andres; Arguedas, Mauricio; Brenes, Hebleen; Buján, Willem; Corrales-Aguilar, Eugenia; Díaz, Cecilia; Echeverri, Ann; Flores-Díaz, Marietta; Gómez, Aarón; Hernández, Andrés; Herrera, María; León, Guillermo; Macaya, Román; Kühne, Arne; Molina-Mora, José Arturo; Mora, Javier; Sanabria, Alfredo; Sánchez, Andrés; Sánchez, Laura; Segura, Álvaro; Segura, Eduardo; Solano, Daniela; Soto, Claudio; Stynoski, Jennifer L; Vargas, Mariángela; Villalta, Mauren; Reusken, Chantal, B. E. M; Drosten, Christian; Gutiérrez, José María; Alape-Girón, Alberto; Drexler, Jan Felix
    SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146–1.078μg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment